GC
KYMR icon

Guggenheim Capital’s Kymera Therapeutics KYMR Stock Holding History

Guggenheim Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Buy
13,088
+2,781
+27% +$220K 0.01% 964
2025
Q4 		$802K Buy
+10,307
New +$696K 0.01% 1047

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Guggenheim Capital's KYMR Position: Q1 2026 in Review

Guggenheim Capital increased its Kymera Therapeutics (KYMR) stake by 27% in Q1 2026, buying an estimated $220K and bringing the position to 13,088 shares worth $1.09M. The position accounts for 0.01% of the portfolio, ranked #964.

Guggenheim Capital first reported a position in KYMR in Q4 2025 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Guggenheim Capital held 13,088 shares of Kymera Therapeutics worth $1.09M as of Q1 2026.
  • Guggenheim Capital bought 2,781 Kymera Therapeutics shares in Q1 2026, an estimated $220K.
  • Kymera Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q1 2026, its #964 holding.
  • Guggenheim Capital first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.